Xoma’s Acquisition Bid Reaches Critical Juncture
Published on 11/07/2025 at 18:02 | Redaktion boerse-global.de
The fate of Xoma Royalty’s proposed acquisition of LAVA Therapeutics hangs in the balance as shareholders convene for a decisive vote. The biotechnology firm’s pursuit of its competitor has reached its final stages, with revised terms significantly altering the transaction’s financial dynamics and sending technical signals about Xoma’s stock performance.
During today’s extraordinary general meeting in Amsterdam, LAVA Therapeutics shareholders are determining whether to accept Xoma Royalty’s takeover offer under substantially modified conditions. The per-share cash consideration has been reduced from the original range of $1.16 to $1.24 down to just $1.04. This downward adjustment is partially offset by the introduction of a contingent value right that could Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
